We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cencora (COR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cencora is a member of our Medical group, which includes 949 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cencora is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for COR's full-year earnings has moved 1.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, COR has gained about 50.4% so far this year. Meanwhile, stocks in the Medical group have gained about 5% on average. This shows that Cencora is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is CorMedix (CRMD - Free Report) . The stock has returned 39% year-to-date.
For CorMedix, the consensus EPS estimate for the current year has increased 108.3% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Cencora belongs to the Medical Services industry, a group that includes 62 individual companies and currently sits at #144 in the Zacks Industry Rank. This group has gained an average of 5.8% so far this year, so COR is performing better in this area.
On the other hand, CorMedix belongs to the Medical - Biomedical and Genetics industry. This 467-stock industry is currently ranked #86. The industry has moved +18.9% year to date.
Investors with an interest in Medical stocks should continue to track Cencora and CorMedix. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cencora (COR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cencora is a member of our Medical group, which includes 949 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cencora is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for COR's full-year earnings has moved 1.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, COR has gained about 50.4% so far this year. Meanwhile, stocks in the Medical group have gained about 5% on average. This shows that Cencora is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is CorMedix (CRMD - Free Report) . The stock has returned 39% year-to-date.
For CorMedix, the consensus EPS estimate for the current year has increased 108.3% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Cencora belongs to the Medical Services industry, a group that includes 62 individual companies and currently sits at #144 in the Zacks Industry Rank. This group has gained an average of 5.8% so far this year, so COR is performing better in this area.
On the other hand, CorMedix belongs to the Medical - Biomedical and Genetics industry. This 467-stock industry is currently ranked #86. The industry has moved +18.9% year to date.
Investors with an interest in Medical stocks should continue to track Cencora and CorMedix. These stocks will be looking to continue their solid performance.